Linda.Bunschoten

About Linda Bunschoten - Global Director of Marketing

Linda has over 20 years of experience uncovering pain points and strategizing with MedTech organisations in order to secure and retain more clients. Her chief thinking responsibilities include translating insight into strategy and ensure that all project activities meet our clients’ quality expectations.
Jul 2018

DIA 2018 Global Annual Meeting: was this year’s theme the most dead-on yet?

By | 2018-07-16T11:41:01+01:00 July 16, 2018|Blog|Comments Off on DIA 2018 Global Annual Meeting: was this year’s theme the most dead-on yet?

The dramatic expansion of prescription drug deaths inspired this year's theme "driving insights to action". Insights that could be deployed through novel disruptive technologies such as Risk-based Quality Management (RBQM). Cyntegrity's Johann Proeve and Nimita Limaye were in Boston and share their observations with us.

Jun 2018

Medical Devices: Managing Risks Beyond Bullet Proof Clinical Evidence

By | 2018-06-12T14:41:15+01:00 June 6, 2018|Blog, Weekly RBM Feature|Comments Off on Medical Devices: Managing Risks Beyond Bullet Proof Clinical Evidence

The EU MDR is setting the stage for busy times ahead. The continuous need for clinical evidence, the increasing complexity of new medical devices, and the size and global nature of medical device trials introduce a greater potential for error. Learn how a risk-based approach enables MedTech manufacturers to better understand, manage and mitigate the growing uncertainties.

May 2018

Interview: “Oncology Trials are Different”

By | 2018-05-03T13:23:27+01:00 May 3, 2018|Blog, News|Comments Off on Interview: “Oncology Trials are Different”

Many risks in clinical trials seem therapy specific. To illustrate this, Dr Johann Proeve shares real life use cases he experienced during his years as Head of Global Data Management at Bayer HealthCare.

May 2018

“OncoRACT” – The First Therapy Specific RACT for Clinical Trials

By | 2018-05-03T13:07:48+01:00 May 1, 2018|Blog, News|Comments Off on “OncoRACT” – The First Therapy Specific RACT for Clinical Trials

Many risks in clinical trials are therapy specific. Because of that, the currently available tools addressing those risks are now becoming therapy specific as well. The first therapy focused risk library Oncology RACT (OncoRACT) recently got available.

Mar 2018

Blockchain in Clinical Trials – The Ultimate Data Notary

By | 2018-03-14T14:00:11+00:00 March 14, 2018|News, White Paper|Comments Off on Blockchain in Clinical Trials – The Ultimate Data Notary

Blockchain technology is the biggest achievement in cryptography of the past decade. Source Data Verification (SDV), which consumes about 20–30% of the clinical trial budget nowadays, will become redundant when blockchain technology disrupts the pharma industry.

Feb 2018

Webinar: Best Practices in Defining KRIs for Clinical Trials

By | 2018-02-13T17:33:55+00:00 February 13, 2018|Webinar|Comments Off on Webinar: Best Practices in Defining KRIs for Clinical Trials

Are your role connected with the controlling the quality, performance or risks of clinical trials? We are delighted to invite you along to this exclusive live webinar and Q&A session on February 23rd, 2018.

Feb 2018

Dr Nimita Limaye: “KRI Wiki is a Path Breaking Initiative”

By | 2018-02-12T11:14:09+00:00 February 7, 2018|News, Weekly RBM Feature|Comments Off on Dr Nimita Limaye: “KRI Wiki is a Path Breaking Initiative”

We are pleased to welcome Dr Nimita Limaye, Project Lead KRI Wiki, to the Cyntegrity team! Key Risk Indicators (KRIs) play a fundamental role in managing risk, you could say they are the “traffic lights” of clinical monitoring. When appropriately selected and calibrated KRIs [...]

Jan 2018

Fake news, fake likes, fake quotes: who or what can I trust these days?

By | 2018-01-04T16:25:54+00:00 January 4, 2018|Blog, Library, Weekly RBM Feature|Comments Off on Fake news, fake likes, fake quotes: who or what can I trust these days?

There is a rapidly growing amount of information to process in clinical research. You could argue whether it adds value viewing and verifying the reliability of each single data point. Dirty data and frauds have always existed but can eventually be marginalised by responsive people and processes.

Jan 2018

Newsletter: Fast-advancing science has opened the era of personalized medicine

By | 2018-01-02T08:37:06+00:00 January 2, 2018|News|Comments Off on Newsletter: Fast-advancing science has opened the era of personalized medicine

More than ever before, well-designed clinical trials are essential to maximize chances of success.

Upcoming Events

  1. SCDM 2018 ANNUAL CONFERENCE – Seattle

    September 23 - September 26
  2. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access